Gilead Sciences: New Prescriptions of Hepatitis C Drugs Slow
November 28, 2014 at 10:16 AM EST
UBS analyst Matthew Roden and team note that new prescriptions for Gilead Sciences’ hepatitis-C drugs are slowing: AP Scripts for Gilead’s Harvoni during the week ending November 21 totaled 4,366, up +21% w/w. This implies a total franchise [total prescriptions, or] TRx (i.e. Sovaldi + Harvoni) of 7,813, up + 5%, and franchise [new prescriptions, [...]